Compare MGM Resorts International (MGM) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MGM Resorts International vs TransMedics Group Inc — how do they compare? MGM Resorts International trades at $40.18 (market cap $10.23B), while TransMedics Group Inc trades at $86.5 (market cap $3.00B). The key difference: MGM Resorts International is far larger — about 3.4× TransMedics Group Inc's market cap, and MGM Resorts International pays a 0.03% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MGM | TMDX | |
|---|---|---|
Market Cap | $10.23B | $3.00B |
Sector | Consumer Cyclical | Technology |
52-Week High | $50.69 | $150.42 |
52-Week Low | $30.72 | $61.99 |
Enterprise Value | $37.53B | $3.39B |
Dividend Yield | 0.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International trades at $40.74, down 1.16% on the day, as the stock faces technical bearish pressure despite strong analyst support. The company reported mixed quarterly earnings with two beats and one miss in recent quarters, while maintaining stable revenue around $17.5 billion. Recent news highlights include BetMGM's football season enhancements and ongoing investigation into Barry Diller's $48.30 per share acquisition offer.
MGM presents a compelling valuation case with a P/S ratio of 0.61 below industry averages, supported by 51% analyst buy ratings and a $51.61 consensus price target offering 27% upside. However, declining profit margins and negative cash flow trends pose fundamental concerns, while the bearish technical outlook suggests near-term pressure. The acquisition investigation adds regulatory uncertainty to the investment thesis.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MGM Resorts International
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
